Jazz Pharmaceuticals to Present New Data at Upcoming ASCO Annual Meeting and EHA Congress

Data to be presented underscore commitment to developing life-changing medicines in hematology/oncology for people with limited or no treatment options

DUBLIN, May 16, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that it will present data from across its hematology/oncology portfolio and pipeline at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 31-June 4, 2019 and at the 24^th Congress of the European Hematology Association (EHA) in Amsterdam from June 13-16, 2019.

"We are excited about our data presentations at both ASCO and EHA as they demonstrate our growing commitment to research in hematology and oncology, and we are also looking forward to data to be presented by the Children's Oncology Group at ASCO from its Phase 1/2 study of liposomal daunorubicin and cytarabine (CPX-351) for children with relapsed acute myeloid leukemia (AML)," said Allen Yang, M.D., Ph.D., senior vice president of clinical development and acting chief medical officer of Jazz Pharmaceuticals. "Jazz is committed to changing the lives of people with limited or no treatment options who are suffering from blood cancers or complications of stem cell transplantation, and we are hopeful our data at both ASCO and EHA will get us one step closer to that goal for the patients who can benefit from our medicines."

"These are exciting results for children with relapsed AML. We plan to study the use of CPX-351 further in newly diagnosed pediatric AML patients through a Children's Oncology Group (COG) Phase 3 study in partnership with Jazz and the National Cancer Institute," said Todd Cooper, D.O., professor of Pediatrics at the University of Washington, School of Medicine; director of the Pediatric Leukemia/Lymphoma Program at Seattle Children's Cancer and Blood Disorders Center, Evans Family Endowed Chair of Pediatric Cancer and chairman of COG's Acute Myeloid Leukemia New Agents Committee.

Highlights at ASCO will include:

• Oral presentation from the Children's Oncology Group examining CPX-351 (liposomal daunorubicin and cytarabine), also known as Vyxeos, followed by fludarabine, cytarabine, and G-CSF (FLAG) for children with relapsed AML.
• Poster presentation summarizing outcomes with CPX-351 versus 7+3 by baseline bone marrow blast percentage in older adults with newly diagnosed, high-risk/secondary AML.

Highlights at EHA will include: